Electromagnetic Stimulation (FREMS) in Patients With Painful Diabetic Neuropathy
Primary Purpose
Painful Diabetic Neuropathy
Status
Completed
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
Frequency-modulated electromagnetic neural stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Painful Diabetic Neuropathy focused on measuring Diabetic neuropathy, Complications of diabetes, Neuropathies, Electromagnetic stimulation, Neuropathic pain
Eligibility Criteria
Inclusion Criteria: type 1 or type 2 diabetes (American Diabetes Association criteria) painful diabetic neuropathy with reduced sensory/motor nerve conduction velocity (i.e., <40 m/sec in at least one nerve trunk of the lower limbs) vibration perception at the big toe >25 V Exclusion Criteria: presence of any concomitant severe disease pregnancy renal disease (serum creatinine >2.0 mg/dL) history or current foot ulcer lower limb arterial disease (ankle-brachial index <0.9) or transcutaneous partial pressure of oxygen <50 mmHg)
Sites / Locations
- San Raffaele Hospital and Scientific Institute
Outcomes
Primary Outcome Measures
Daytime and night-time pain scores assessed at baseline, after FREMS/placebo, and 4 month follow-up
Secondary Outcome Measures
Measurements of the following parameters were made at baseline, after FREMS/placebo, and 4 month follow-up:
Motor and sensory nerve conduction velocity
Sensory tactile perception by monofilament
Foot vibration perception threshold by biothesiometer
Quality of life by SF-36 instrument
Cutaneous microvascular flow by laser doppler
Partial tissue tension of oxygen and carbon dioxide by oxymetry
Full Information
NCT ID
NCT00337324
First Posted
June 14, 2006
Last Updated
June 14, 2006
Sponsor
IRCCS San Raffaele
Collaborators
Lorenz Biotech S.p.A., University Of Perugia
1. Study Identification
Unique Protocol Identification Number
NCT00337324
Brief Title
Electromagnetic Stimulation (FREMS) in Patients With Painful Diabetic Neuropathy
Official Title
Clinical Assessment of Transcutaneous Neurostimulation and Biofeedback (FREMS)in Patients With Diabetic Neuropathy
Study Type
Interventional
2. Study Status
Record Verification Date
March 2002
Overall Recruitment Status
Completed
Study Start Date
March 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
May 2004 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
IRCCS San Raffaele
Collaborators
Lorenz Biotech S.p.A., University Of Perugia
4. Oversight
5. Study Description
Brief Summary
We postulate that frequency-modulated electromagnetic stimulation (FREMS) may decrease pain in patients with painful diabetic neuropathy.
Detailed Description
The stuy was designed as a randomized, double-blind, placebo-controlled cross-over trial. Each patient received two series of ten treatments of either FREMS or placebo in random sequence, with each series lasting no more than three weeks. Primary outcomes (daytime and night-time pain scores) an secondary outcomes (Motor and sensory nerve conduction velocity, sensory tactile perception, foot vibration perception threshold, quality of life, cutaneous microvascular flow, partial tissue tension of oxygen and carbon dioxide) were measured at baseline, after FREMS/placebo series and after 4 months follow-up.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Painful Diabetic Neuropathy
Keywords
Diabetic neuropathy, Complications of diabetes, Neuropathies, Electromagnetic stimulation, Neuropathic pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
38 (false)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
Frequency-modulated electromagnetic neural stimulation
Primary Outcome Measure Information:
Title
Daytime and night-time pain scores assessed at baseline, after FREMS/placebo, and 4 month follow-up
Secondary Outcome Measure Information:
Title
Measurements of the following parameters were made at baseline, after FREMS/placebo, and 4 month follow-up:
Title
Motor and sensory nerve conduction velocity
Title
Sensory tactile perception by monofilament
Title
Foot vibration perception threshold by biothesiometer
Title
Quality of life by SF-36 instrument
Title
Cutaneous microvascular flow by laser doppler
Title
Partial tissue tension of oxygen and carbon dioxide by oxymetry
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
type 1 or type 2 diabetes (American Diabetes Association criteria)
painful diabetic neuropathy with reduced sensory/motor nerve conduction velocity (i.e., <40 m/sec in at least one nerve trunk of the lower limbs)
vibration perception at the big toe >25 V
Exclusion Criteria:
presence of any concomitant severe disease
pregnancy
renal disease (serum creatinine >2.0 mg/dL)
history or current foot ulcer
lower limb arterial disease (ankle-brachial index <0.9) or transcutaneous partial pressure of oxygen <50 mmHg)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emanuele Bosi, MD
Organizational Affiliation
San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milano (Italy)
Official's Role
Principal Investigator
Facility Information:
Facility Name
San Raffaele Hospital and Scientific Institute
City
Milano
State/Province
(Mi)
ZIP/Postal Code
20132
Country
Italy
12. IPD Sharing Statement
Citations:
PubMed Identifier
15834546
Citation
Bosi E, Conti M, Vermigli C, Cazzetta G, Peretti E, Cordoni MC, Galimberti G, Scionti L. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia. 2005 May;48(5):817-23. doi: 10.1007/s00125-005-1734-2. Epub 2005 Apr 15.
Results Reference
result
PubMed Identifier
18403219
Citation
Conti M, Peretti E, Cazzetta G, Galimberti G, Vermigli C, Pola R, Scionti L, Bosi E. Frequency-modulated electromagnetic neural stimulation enhances cutaneous microvascular flow in patients with diabetic neuropathy. J Diabetes Complications. 2009 Jan-Feb;23(1):46-8. doi: 10.1016/j.jdiacomp.2008.02.004. Epub 2008 Apr 10.
Results Reference
derived
Learn more about this trial
Electromagnetic Stimulation (FREMS) in Patients With Painful Diabetic Neuropathy
We'll reach out to this number within 24 hrs